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Abstract 
Background: Arm and shoulder problems (ASP), including lymphedema, were common among women with breast 
cancer in high‑income countries before sentinel lymph node biopsy became the standard of care. Although ASP 
impair quality of life, as they affect daily life activities, their frequency and determinants in Sub‑Saharan Africa remain 
unclear.
Methods: All women newly diagnosed with breast cancer at the Namibian, Ugandan, Nigerian, and Zambian sites 
of the African Breast Cancer‑Disparities in Outcomes (ABC‑DO) cohort study were included. At each 3‑month follow‑
up interview, women answered the EORTC‑QLQ‑Br23 questionnaire, including three ASP items: shoulder/arm pain, 
arm stiffness, and arm/hand swelling. We estimated the cumulative incidence of first self‑reported ASP, overall and 
stratified by study and treatment status, with deaths treated as competing events. To identify determinants of ASP, we 
estimated cause‑specific hazard ratios using Cox models stratified by study site.
Results: Among 1476 women, up to 4 years after diagnosis, 43% (95% CI 40–46), 36% (33–38) and 23% (20–25), 
respectively, self‑reported having experienced arm/shoulder pain, stiffness and arm/hand swelling at least once. 
Although risks of self‑reported ASP differed between sites, a more advanced breast cancer stage at diagnosis, having a 
lower socioeconomic position and receiving treatment increased the risk of reporting an ASP.
Conclusion: ASP are very common in breast cancer survivors in Sub‑Saharan Africa. They are influenced by different 
factors than those observed in high‑income countries. There is a need to raise awareness and improve management 
of ASP within the African setting.
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Background
Breast cancer is the most commonly diagnosed cancer 
in women worldwide [1]. In 2020, 129,000 Sub-Saharan 
African women were newly diagnosed with this cancer, 
and the incidence is projected to increase [1]. Before 
the development of sentinel lymph node biopsy, in 
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high-income countries (HICs), arm and shoulder prob-
lems (ASP), defined by stiffness, pain and swelling, were 
frequent among breast cancer patients and survivors. In 
this context, ASP were typically ipsilateral and occurred 
due to axillary lymph node dissection, mastectomy, 
chemotherapy, and radiotherapy. ASP risk factors also 
included number of lymph nodes removed, older age, and 
high body mass index (BMI) [2–4]. Although ASP are not 
life threatening, they impair women’s quality of life in the 
long-term as they affect daily life and activities [5].
In Sub-Saharan Africa (SSA), the frequency of ASP 
in breast cancer survivors is unclear. A recent meta-
analysis that aimed to assess the prevalence and inci-
dence of lymphedema (i.e. arm swelling) in low- and 
middle-income countries (LMICs), which included only 
one study from SSA, could not obtain a pooled estimate 
because of large between-study heterogeneity [6]. This 
was due to the differences in study designs, in measure-
ment methods and definitions, and duration of follow-
up. Since this meta-analysis, a few additional studies 
from SSA have been published but none was designed to 
estimate the frequency of ASP, and they were too small 
to allow a thorough investigation of ASP risk factors [4, 
7–10].
Risk factors for ASP in SSA may differ from that of 
HICs because of the very advanced stage at breast can-
cer diagnosis, different treatment courses or the broader 
environment including the physical burden in daily life 
or infectious agents [11–13]. In this setting, a substantial 
proportion of women do not receive timely, complete or 
high-quality treatment [14]. For instance, surgical proce-
dures commonly used in HICs, such as sentinel lymph 
node biopsy and breast-conserving surgery, are less often 
performed in SSA where mastectomy and axillary lymph 
node dissection are the predominant surgical procedures. 
Moreover, ASP can already be present at the time of diag-
nosis, before treatment initiation, due to the physical 
impact of extremely large tumour sizes and high number 
of affected lymph nodes at diagnosis. Furthermore, it is 
conceivable that risk factors may vary across different 
ethnic groups.
In this context, the present study aimed to estimate the 
frequency and determinants of ASP after a breast cancer 
diagnosis within the African Breast Cancer-Disparities 
in Outcomes (ABC-DO) cohort, a prospective cohort of 
women with breast cancer in five SSA countries.
Methods
Study design and data collection
This study was part of the African Breast Cancer-Dis-
parities in Outcomes (ABC-DO) study, a prospective 
multicentric hospital-based cohort study of disparities 
in survival in women after a diagnosis of breast cancer. 
ABC-DO was conducted in Nigeria, Zambia, Uganda, 
Namibia and South Africa and its protocol is available 
elsewhere [15]. In brief, from September 2014 to early 
2017, all women aged 18 and above who visited one of 
the participating hospitals and were suspected of hav-
ing breast cancer were invited to participate. Of 2313 
women recruited with suspected breast cancer, 2228 had 
the disease confirmed by histology, cytology or clinically. 
Overall, 2212 (99%) of those eligible women accepted to 
participate and were included in ABC-DO.
Data collection
At baseline, data on women’s sociodemographic char-
acteristics, comorbidities, breast cancer risk factors and 
health attitudes, knowledge and beliefs were collected via 
an interviewer-administered questionnaire. The woman 
agreed to be contacted thereafter every three months 
by mobile phone. MHealth technology was used for all 
real-time data collection and to facilitate contact with 
women or their next of kin every three-months, using a 
standardized protocol that minimized losses to follow-
up [16]. At each 3-month follow-up contact, data on 
treatment (surgery, radiotherapy, chemotherapy, and 
endocrine therapy) were collected from both medical 
records and self-reports. The woman also answered the 
EORTC-QLQ-Br23 questionnaire, an internationally 
validated questionnaire to assess quality of life of women 
with breast cancer [17]. For the primary ASP outcomes, 
we used responses to the three questions pertaining, at 
each trimonthly contact, to the past week “Did you have 
pain in your arm or shoulder?”; “Did you have a swollen 
arm or hand?” and “Was it difficult to raise your arm or 
to move it sideways?” for information on arm or shoulder 
pain, arm or hand swelling and arm stiffness, respectively. 
Each of the three items were rated on a four-point Likert 
scale of “not at all”, “a little”, “quite a bit” and “very much”. 
In the present analysis, each ASP was considered present 
if rated “quite a bit” or “very much” and absent otherwise, 
as was previously done in other studies [5, 18, 19].
Inclusion criteria and exclusion criteria
For the purpose of this analysis, all women enrolled into 
ABC-DO were included except those from South Africa 
(n = 675) because the regular follow-up at this site did 
not systematically ascertain ASP. Prevalent breast cancer 
cases (i.e. women with a previous diagnosis of breast can-
cer more than two years before enrolment n = 57) or who 
were lost to follow-up immediately after diagnosis were 
also excluded (n = 4), leaving 1476 women in the analysis.
Determinants of ASP
Sociodemographic characteristics, tumour characteris-
tics and type of treatment received, regardless of whether 
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treatment was completed or not, were assessed in rela-
tion to each ASP self-reporting. These included: (1) Five 
population groups defined by country and ethnicity 
(Namibia black, Namibia non-black, Uganda, Nige-
ria and Zambia); (2) TNM stage at diagnosis (stage I/
II, III, IV and unknown); (3) age at diagnosis (continu-
ous, < 50  years and ≥ 50); (4) highest educational level 
(none or primary school, secondary or high school, uni-
versity or technical degree); (5) body mass index (BMI) 
calculated from measured height and weight at baseline 
(continuous and < 25 kg/m2, [25–30[ Kg/m2, ≥ 30 kg/m2); 
(6) self-reported HIV status at baseline (positive, negative 
or unknown); (7) Self-reported hypertension (yes, no) at 
baseline based on the question “Have you ever been diag-
nosed with hypertension?”; (8) treatment and specific 
types of treatment (surgery, radiotherapy, chemotherapy, 
endocrine therapy) were considered as categorical time-
varying variable, and we performed a Lexis expansion to 
take into account change in treatment status over time 
(prior treatment: yes/no/unknown) [20].
Statistical analysis
For each ASP, we examined time to the first report of the 
ASP. Follow-up started from the date of diagnosis and 
ended on the date of interview when the ASP was first 
reported, the date of death (as a competing event), the 
date when 4-year follow-up was reached, date of last live 
contact or 1st January 2020, whichever came first. Using 
this time scale, we calculated the cumulative incidence of 
each ASP, overall and stratified by study site, from time 
since diagnosis prior to receiving treatment.
To identify potential determinants for each ASP, we 
fitted Cox proportional hazards models. Crude models 
were fitted for all potential determinants adjusted for 
age as a continuous variable and stratified by study site. 
We used likelihood ratio tests to determine whether age, 
BMI, educational level and tumour stage would be better 
explained as continuous or categorical. For each ASP, a 
multivariate model was fitted mutually adjusting for the 
same set of covariates (i.e. age, BMI, educational level, 
stage at diagnosis and treatment received). These models 
yielded adjusted cause-specific hazard ratios (CHR) esti-
mates which shows the relative change in the rate of ASP 
according to each determinant, in women who are cur-
rently alive.
To assess the robustness of the findings we conducted 
further analysis to estimate: (1) cumulative incidence of 
the first self-reported ASP stratified by type of ASP and 
tumour stage at diagnosis; (2) cumulative incidence using 
a more strict definition of ASP based on time to the first 
report of a specific ASP in a 12-month period when there 
were multiple reports of that ASP (not necessarily con-
secutive); for the latter analyses, cumulative incidences 
are reported up to three years after diagnosis to allow 
for a subsequent multiple report within the following 
12-months (maximal follow-up 4-years). In addition, we 
fitted the multivariate models described above but con-
ditional on women having survived the first 6  months 
after diagnosis and excluding those with metastatic dis-
ease, as these women might not have received the same 
treatment as less advanced cases, and might have been 
at higher risk of reporting ASP. Lastly, to better under-
stand the respective impacts of breast cancer itself and 
treatment on occurrence of ASP, we estimated one-year 
cumulative incidences of self-reported ASP prior to and 




Of the 1476 women included in this analysis, there 
were 477 Namibian, 418 Ugandan, 383 Nigerian and 
198 Zambian women. Table  1 presents baseline char-
acteristics of these women. Briefly, mean age at diagno-
sis was 50.3 years (SD = 13.7). About half of the women 
had none or primary school education level (N = 657, 
44.5%), and most were diagnosed with late-stage breast 
cancer (N = 1106, 75.0%). Concerning comorbidities, 342 
(23.2%) of women were obese, 144 (9.8%) were HIV-pos-
itive and 426 (28.9%) had hypertension. Although there 
were important between-country disparities in treatment 
received, overall, 171 women (11.6%) did not receive 
any treatment, 928 (62.9%) received chemotherapy, 841 
(57.0%) had surgery, 694 (47.0%) endocrine therapy, and 
465 (31.5%) radiotherapy.
Distribution of self‑reported ASP
Of the 1476 women included in this analysis, 162 (11.0%) 
died before completing the first follow-up interview. 
Overall, 743 (50.3%) of the 1476 women reported at least 
once an ASP, 618 (41.9%) arm/shoulder pain, 516 (35.0%) 
arm stiffness and 319 (21.6%) arm/hand swelling (Fig. 1). 
Of the 238 (16.1%) women who reported having experi-
enced two different ASP, either concomitantly or at dif-
ferent follow-up time points, 187 (78.6%) reported both 
arm/shoulder pain and arm stiffness, 33 (13.9%) reported 
pain and arm/hand swelling, and 18 (7.6%) reported both 
arm stiffness and swelling. Finally, 236 (16.0%) women 
reported having experienced all three ASP.
Cumulative incidence of self‑reported ASP
Four years after being diagnosed with breast cancer, 
cumulative incidences of shoulder/arm pain, stiffness 
and arm/hand swelling were 43.0% (95% CI 40.4–45.6), 
35.8% (33.4–38.3) and 22.5% (20.4–24.8), based on 618, 
516 and 319 women, respectively (Table  2). Among the 
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171 untreated women, these cumulative incidences were, 
respectively, 29.2% (21.9–36.8), 21.2% (14.7–28.4) and 
15.3% (9.8–21.9) based on 47, 33 and 23 women, respec-
tively (Additional file 1: Table S1). In comparison to prior 
to receiving any treatment, cumulative incidences of 
ASP were two to three times higher after treatment start 
(Additional file 2: Table S2 and Additional file 3: Fig. S1). 
About half of all women who reported a specific ASP had 
multiple reports of that ASP within a 12-months period 
(Additional file  4: Fig. S2). The rate at which new ASPs 
Table 1 Baseline characteristics of the newly diagnosed breast cancer patients enrolled in the ABC‑DO cohort study
a In ABC-DO, surgeries were mostly mastectomies (82%) as compared to lumpectomies. These were, respectively, 80%, 92%, 91%, 50% and 94% in Namibian Non-
Black, Namibian Black, Ugandan, Nigerian, and Zambian women
Namibia Non‑




Uganda (N = 418) Nigeria (N = 383) Zambia (N = 198) Overall (N = 1476)
N (%) N (%) N (%) N (%) N (%) N (%)
Mean age at diagnosis, years (SD) 56.7 (12.5) 52.6 (15.0) 48.4 (12.7) 48.7 (12.3) 50.0 (14.8) 50.3 (13.7)
BMI, kg/m2
 < 25 31 (32.0) 162 (42.6) 201 (48.1) 162 (42.3) 81 (40.9) 637 (43.2)
[25–30[ 20 (20.6) 98 (25.8) 148 (35.4) 107 (27.9) 53 (26.8) 426 (28.9)
30 + 41 (42.3) 102 (26.8) 60 (14.4) 94 (24.5) 45 (22.7) 342 (23.2)
Unknown 5 (5.2) 18 (4.7) 9 (2.2) 20 (5.2) 19 (9.6) 71 (4.8)
Education
None/primary 13 (13.4) 197 (51.8) 242 (57.9) 102 (26.6) 103 (52.0) 657 (44.5)
Secondary/high school 46 (47.4) 132 (34.7) 126 (30.1) 144 (37.6) 54 (27.3) 502 (34.0)
Technical/university 38 (39.2) 51 (13.4) 50 (12.0) 137 (35.8) 41 (20.7) 317 (21.5)
HIV status
Positive 3 (3.1) 53 (13.9) 48 (11.5) 9 (2.3) 31 (15.7) 144 (9.8)
Hypertension
Yes 49 (50.5) 155 (40.8) 65 (15.6) 100 (26.1) 57 (28.8) 426 (28.9)
Tumour stage at diagnosis
Localized (stage TNM I/II) 48 (49.5) 73 (19.2) 96 (23.0) 39 (10.2) 19 (9.6) 275 (18.6)
Locally advanced (stage TNM III) 43 (44.3) 247 (65.0) 226 (54.1) 256 (66.8) 131 (66.2) 903 (61.2)
Metastatic (stage TNM IV) 6 (6.2) 60 (15.8) 64 (15.3) 60 (15.7) 13 (6.6) 203 (13.8)
Unknown 0 (0.0) 0 (0.0) 32 (7.7) 28 (7.3) 35 (17.7) 95 (6.4)
Treated
No 0 (0.0) 1 (0.3) 36 (8.6) 95 (24.8) 39 (19.7) 171 (11.6)
Yes 97 (100.0) 376 (98.9) 359 (85.9) 262 (68.4) 140 (70.7) 1234 (83.6)
Unknown 0 (0.0) 3 (0.8) 23 (5.5) 26 (6.8) 19 (9.6) 71 (4.8)
Surgerya
No 9 (9.3) 88 (23.2) 125 (29.9) 150 (39.2) 85 (42.9) 457 (31.0)
Yes 84 (86.6) 244 (64.2) 240 (57.4) 183 (47.8) 90 (45.5) 841 (57.0)
Unknown 4 (4.1) 48 (12.6) 53 (12.7) 50 (13.1) 23 (11.6) 178 (12.1)
Radiotherapy
No 24 (24.7) 72 (18.9) 276 (66.0) 308 (80.4) 130 (65.7) 810 (54.9)
Yes 71 (73.2) 287 (75.5) 56 (13.4) 11 (2.9) 40 (20.2) 465 (31.5)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Endocrine therapy
No 18 (18.6) 76 (20.0) 194 (46.4) 210 (54.8) 109 (55.1) 607 (41.1)
Yes 76 (78.4) 276 (72.6) 151 (36.1) 127 (33.2) 64 (32.3) 694 (47.0)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Chemotherapy
No 26 (26.8) 64 (16.8) 74 (17.7) 164 (42.8) 55 (27.8) 383 (25.9)
Yes 70 (72.2) 290 (76.3) 283 (67.7) 170 (44.4) 115 (58.1) 928 (62.9)
Unknown 1 (1.0) 26 (6.8) 61 (14.6) 49 (12.8) 28 (14.1) 165 (11.2)
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Fig. 1 Crude proportion (n = 1476) of women who self‑reported at least once having experienced ASP, by type of ASP, in ABC‑DO
Table 2 Four years post‑diagnosis cumulative incidence of first self‑reported ASP in ABCDO, by country and treatment
ASP arm and shoulder problems, CI confidence interval
No. women with outcome/total 
(competing deaths)
Time at risk (person‑years) ASP type‑specific cumulative 
incidence at 4 years since diagnosis 
(95% CI)
Shoulder/arm pain
All sites/ethnicities 618/1476 (449) 680 43.0 (40.4–45.6)
Namibia non‑black 25/97 (12) 42 26.0 (17.7–35.1)
Namibia black 151/380 (100) 218 40.3 (35.3–45.2)
Uganda 214/418 (119) 174 51.8 (46.9–56.5)
Nigeria 162/383 (141) 168 44.0 (38.7–49.3)
Zambia 66/198 (77) 77 35.1 (28.3–42.0)
Arm stiffness
All sites/ethnicities 516/1476 (505) 628 35.8 (33.4–38.3)
Namibia non‑black 26/97 (13) 34 26.9 (18.5–36.0)
Namibia black 148/380 (106) 209 39.3 (34.3–44.2)
Uganda 184/418 (133) 201 44.7 (39.8–49.5)
Nigeria 106/383 (176) 124 28.8 (24.2–33.6)
Zambia 52/198 (77) 60 27.9 (21.6–34.5)
Arm/hand swelling
All sites/ethnicities 319/1476 (602) 464 22.5 (20.4–24.8)
Namibia non‑black 13/97 (16) 29 13.7 (7.7–21.4)
Namibia black 81/380 (130) 144 21.9 (17.8–26.3)
Uganda 103/418 (180) 122 25.1 (21.0–29.4)
Nigeria 84/383 (191) 120 23.3 (19.0–28.0)
Zambia 38/198 (85) 50 20.4 (15.0–26.5)
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were reported declined over time, with half of the 4-year 
cumulative reporting incidence occurring within the first 
year of diagnosis (Additional file 4: Fig. S2).
Determinants of first self‑reported ASP
Determinants of first self-reported ASP, separately for 
each ASP type, are described in detail in Table  3, and 
in Additional file  5: Table  S3 and Additional file  6: Fig. 
S3. After adjusting on all potential determinants of 
ASP identified in crude analysis, there were important 
between-country and between-ethnicity disparities. Rel-
ative to Namibia black women, the risk of a first ASP self-
report was lowest for non-black Namibians for all three 
ASP and highest for Ugandan women for all ASP (fully 
adjusted CHR 2.00; 95%CI 1.61–2.48 for shoulder/arm 
pain, 1.52 (1.21–1.90) for arm stiffness and 1.59 (1.18–
2.15) for arm/hand swelling), and for Nigerian women for 
all ASP except arm stiffness.
Tumour stage at diagnosis was the main determinant 
of ASP self-reporting (Table 3 and Additional file 7: Fig. 
S4), with women diagnosed with a more advanced stage 
tumour having an increased risk of self-reporting an ASP 
(p for heterogeneity < 0.0001 for all three types of ASP). 
The strongest association was observed for arm swelling 
– relative to women with localized disease at diagnosis, 
the risk of self-reporting this ASP was two times higher 
(CHR 1.98; 95% CI 1.40–2.79) for women with locally 
advanced cancers, and four times higher (4.02; 2.59–6.23) 
for those with metastatic disease.
The risk of self-reporting an ASP was inversely asso-
ciated with the woman’s educational level for all ASP 
(Table  3), being particularly marked for shoulder/arm 
pain and arm stiffness (p for trend < 0.0001). Relative to 
women with a university level, those with only primary 
school level or less were 94% (fully adjusted CHR 1.94; 
95% CI 1.51–2.49) more likely to self-report shoulder/
arm pain and 77% (1.77; 1.34–2.33) more likely to self-
report arm stiffness. Older age at breast cancer diagnosis 
(≥ 50 years) tended to be associated with a higher report-
ing of shoulder/arm pain (CHR 1.18; 95% CI 0.99–1.39, 
p = 0.06), but there was no evidence that the risk of self-
reporting any of the three ASPs depended on a woman’s 
BMI, HIV status or hypertension.
Receiving treatment was associated with the likeli-
hood of reporting shoulder/arm pain (CHR 1.37; 95% 
CI 1.08–1.72) and arm/hand swelling (CHR 1.67; 95% 
CI 1.16–2.41). These associations were driven by chemo-
therapy, which increased the risk of reporting an ASP by 
about 50% for both shoulder/arm pain (CHR 1.48; 95% 
CI 1.21–1.82) and arm stiffness (1.48; 1.17–1.87), and 
by up to 65% for arm/hand swelling (1.65; 1.22–2.23). In 
contrast, surgery decreased the risk of reporting a shoul-
der/arm pain by about 25% (0.76; 0.63–0.92). However, 
when stratifying the analysis according to tumour stage 
at diagnosis, these treatment effects were only observed 
in women with late stage cancers (Additional file  8: 
Table S4).
After excluding women with metastatic cancer and 
conditioning the analysis on 6-month survival, results 
remained similar. However, receiving radiotherapy 
reduced the risk of reporting an arm stiffness, and this 
association was strongest in women diagnosed with a 
localized breast cancer (Additional file 8: Table S4).
Discussion
Main findings
Using data from a large and multi-centric cohort, we 
obtained robust estimates of the frequency of ASP in 
women after a breast cancer diagnosis across multi-
ple SSA settings and examined their determinants. To 
our knowledge, our study is the first in SSA to show 
that ASP occur not only after receiving treatment but 
may also be present prior to treatment. The frequency 
of self-reported ASP was high in this setting, but with 
important between-country disparities. Overall, about 
1 out of 2 women reported having experienced a mod-
erate to severe ASP at least once during the follow-up 
period. Shoulder/arm pain was the most commonly 
reported ASP, followed by arm stiffness and arm/hand 
swelling, and most often, women reported multiple ASP 
types either concomitantly or at different follow-up time 
points. Among women who reported having experienced 
ASP, about half reported the same type of ASP more than 
once over time. More advanced breast cancer stage at 
diagnosis, older age, having a lower socioeconomic posi-
tion and receiving treatment increased the risk of self-
reported ASP.
ASP frequency in SSA
Our estimates of ASP frequency in SSA were higher than 
those previously reported in the region, maybe due to dif-
ferences in study designs, sample sizes, ASP assessment 
methods and follow-up durations [4, 9, 10]. There were, 
however, important between-country disparities in ASP 
reporting, with Namibian non-black women reporting 
ASP the least, and Ugandan women the most. These dif-
ferences, which remained after controlling for the earlier 
stage at breast cancer diagnosis of non-Namibian black 
women, may reflect over- or under-reporting of ASP for 
cultural reasons, variations in data collection quality or 
in interpretation of EORTC-QLQ-Br23 questions across 
sites, and/or ethnic differences in a woman’s susceptibil-
ity to develop an ASP, because within Namibia, non-black 
women tended to report less ASP than black women. 
Lifestyle and treatment management and aftercare will 
also differ substantially.
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Table 3 Fully adjusted associations of baseline sociodemographic, tumour and treatment characteristics with first self‑reported ASP
No. women with outcome/total Fully adjusted CHR (95%CI)a,b
Shoulder/arm 
pain
Arm stiffness Arm/hand 
swelling
Shoulder/arm pain Arm stiffness Arm/hand swelling
Study site, 
ethnicity
Namibia Black 151/380 148/380 81/380 1 1 1 0.001
Namibia Non‑
Black
25/97 26/97 13/97 0.71 (0.46–1.10)  < 0.0001 0.78 (0.50–1.20) 0.0002 0.68 (0.37–1.24)
Uganda 214/418 184/418 103/418 2.00 (1.61–2.48) 1.52 (1.21–1.90) 1.59 (1.18–2.15)
Nigeria 162/383 106/383 84/383 1.88 (1.48–2.39) 1.06 (0.81–1.39) 1.69 (1.21–2.34)
Zambia 66/198 52/198 38/198 1.19 (0.88–1.61) 0.91 (0.66–1.27) 1.35 (0.90–2.03)
Age at diagnosis 
(years)
 < 50 307/780 255/780 157/780 1 0.06 1 0.23 1 0.10
 ≥ 50 311/696 261/696 162/696 1.18 (0.99–1.39) 1.12 (0.93–1.35) 1.22 (0.96–1.53)
per 10 years 
increase
618/1476 516/1476 319/1476 1.04 (0.98–1.11) 0.21 1.04 (0.97–1.11) 0.31 1.04 (0.95–1.13) 0.43
BMI (Kg/m2)
 < 25 273/637 229/637 129/637 1 0.37 1 0.30 1 0.41
[25–30[ 176/426 144/426 95/426 0.88 (0.72–1.06) 0.89 (0.72–1.09) 1.04 (0.79–1.35)
30 + 140/342 120/342 80/342 0.99 (0.80–1.21) 1.07 (0.85–1.34) 1.21 (0.91–1.60)
per 5 kg/m2 
increase




106/317 84/317 66/317 1 1 1 0.07
Secondary/
high school
196/502 161/502 95/502 1.48 (1.16–1.88) 1.41 (1.08–1.84) 1.08 (0.78–1.49)
None/Primary 
school




618/1476 516/1476 319/1476 1.38 (1.22–1.56)  < 0.0001 1.32 (1.16–1.51)  < 0.0001 1.20 (1.02–1.41) 0.03





562/1332 460/1332 291/1332 1 0.85 1 0.14 1  > 0.99




No 432/1050 363/1050 215/1050 1 0.11 1 0.99 1 0.15
Yes 186/426 153/426 104/426 1.17 (0.96–1.42) 1.00 (0.81–1.23) 1.22 (0.93–1.58)
Tumour stage at 
diagnosis
Localized 91/275 79/275 40/275 1  < 0.0001 1  < 0.0001 1  < 0.0001
Locally 
advanced
413/903 343/903 207/903 1.70 (1.35–2.14) 1.66 (1.29–2.13) 1.98 (1.40–2.79)
Metastatic 79/203 68/203 48/203 2.44 (1.78–3.33) 2.69 (1.92–3.77) 4.02 (2.59–6.23)
Prior treatment
No 105/237 75/221 41/197 1 0.01 1 0.08 1 0.01
Yes 496/1168 429/1184 270/1208 1.37 (1.08–1.72) 1.27 (0.97–1.67) 1.67 (1.16–2.41)
Prior surgeryc
No 248/512 185/497 116/482 1 0.01 1 0.21 1 0.19
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Sociodemographic determinants of ASP
In ABC-DO, women with lower educational level were 
at higher risk of self-reporting an ASP, irrespective of 
tumour stage at diagnosis, maybe due to lower breast 
cancer awareness and higher physical demands of their 
daily cores [11]. Women over 50  years of age tended to 
be at higher risk of self-reporting a shoulder/arm pain, 
which contrasts with the findings from a South African 
study in which the prevalence of ASP decreased with age 
[4]. Also, we did not find an association between BMI 
and ASP, possibly because it was only measured once, at 
breast cancer diagnosis, and we were not able to capture 
its change over time in the analysis [21].
Medical determinants of ASP
In our study, a higher breast cancer stage at diagnosis 
was the most important determinant of self-reporting 
an ASP. In contrast to HICs where most women have 
Table 3 (continued)
No. women with outcome/total Fully adjusted CHR (95%CI)a,b
Shoulder/arm 
pain
Arm stiffness Arm/hand 
swelling
Shoulder/arm pain Arm stiffness Arm/hand swelling
Yes 309/786 280/801 173/816 0.76 (0.63–0.92) 0.87 (0.70–1.08) 0.83 (0.63–1.09)
Prior radio-
therapy
No 397/854 316/850 186/825 1 0.60 1 0.22 1 0.59
Yes 147/421 135/425 86/450 1.07 (0.83–1.38) 0.85 (0.65–1.10) 1.10 (0.77–1.59)
Prior chemo-
therapy
No 184/438 133/418 79/400 1 0.0002 1 0.001 1 0.001
Yes 370/873 327/893 206/911 1.48 (1.21–1.82) 1.48 (1.17–1.87) 1.65 (1.22–2.23)
Prior endocrine 
therapy
No 328/703 247/672 151/649 1 0.59 1 0.87 1 0.45










Yes vs. No 419/1037 366/1039 214/1045 1.58 (1.14–2.18) 0.01 1.37 (0.95–1.98) 0.10 1.39 (0.86–2.24) 0.18
Prior surgery
Yes vs. No 280/769 254/771 149/776 0.77 (0.62–0.95) 0.02 0.92 (0.73–1.17) 0.50 0.84 (0.62–1.14) 0.26
Prior radio-
therapy
Yes vs. No 125/382 116/380 76/401 0.83 (0.64–1.09) 0.18 0.70 (0.53–0.92) 0.01 0.91 (0.62–1.32) 0.61
Prior chemo-
therapy
Yes vs. No 339/813 300/813 178/821 1.67 (1.31–2.12)  < 0.0001 1.52 (1.17–1.97) 0.002 1.59 (1.12–2.25) 0.01
Prior endocrine 
therapy
Yes vs. No 218/576 200/582 118/597 0.97 (0.79–1.19) 0.74 0.99 (0.80–1.23) 0.93 0.87 (0.65–1.15) 0.32
CHR cause-specific hazard ratio, CI confidence interval
a For study site, age, BMI, education, tumour stage and prior treatment: fully adjusted CHRs are stratified on study site, and adjusted on age (continuous), BMI 
(categorical), education (continuous), tumour stage (categorical), and prior treatment
b For Prior surgery, prior radiotherapy, prior chemotherapy, Prior endocrine therapy: fully adjusted CHRs are stratified on study site, and adjusted on age (continuous), 
BMI (categorical), education (continuous), tumour stage (categorical), and mutually adjusted on each specific treatment type
c Of women who received a surgery and reported an arm/shoulder pain during the follow-up, 84% had a mastectomy. For arm stiffness and arm/hand swelling, these 
percentages were, respectively, 89% and 87%
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an early stage diagnosis, late stage diagnosis for breast 
cancer is common in SSA due to low breast cancer 
awareness among both women and healthcare pro-
fessionals, and long delays to presentation of sympto-
matic women to a healthcare provider, final diagnosis 
and treatment initiation, with disadvantaged popula-
tions being particularly affected [11, 12, 22, 23]. In our 
cohort, three quarters of women had a late stage breast 
cancer at diagnosis, with nearly half having a tumour 
size over five centimetres and about two thirds positive 
lymph nodes at diagnosis. It is plausible that, the larger 
tumours, and the increased number of affected lymph 
nodes in women with an advanced breast cancer, may 
have favoured ASP development, including prior to 
receiving treatment [24, 25].
Receiving treatment also increased the risk of report-
ing an ASP in women with advanced breast cancers, 
but our study may have lacked statistical power to 
detect an association in women with localized breast 
cancers. This association may partly be due to remain-
ing unmeasured systematic differences between women 
who underwent specific treatment types and those who 
did not. The treatment effect was driven by chemo-
therapy, while surgery was associated with lower self-
reporting of shoulder/arm pain, in line with what was 
found in another South African study with similar 
cohort characteristics [4]. Indeed, in our study, chem-
otherapy was the first treatment given and its initia-
tion may have preceded the first follow-up interview. 
Women who received chemotherapy had higher SEP 
indicators and higher stage at diagnosis than women 
who did not. While chemotherapy is usually admin-
istered through central lines in HICs, these are not 
available in most LMICs where peripheral intravenous 
perfusions are used instead, as in our cohort. It is there-
fore possible that chemotherapy drugs administered 
through a peripheral line engender side-effects such as 
local inflammation and ASP. However, our study was 
not designed to assess treatment effects and thus we 
cannot exclude the possibility that the observed chemo-
therapy-ASP association may be due to local symptoms 
caused by the breast cancer itself [26, 27]. Despite the 
more invasive surgical procedures often used in SSA, 
as compared to HICs, such as mastectomy and axil-
lary lymph node dissection, it is possible that surgical 
removal of large tumours or a high number of affected 
lymph nodes relieve pain in women with advanced 
disease [4, 8, 28, 29]. We also found that women diag-
nosed with an early stage cancer who survived at least 
six months had lower risk of self-reporting an ASP after 
receiving radiotherapy, which contrasts with previ-
ous studies results and needs to be further investigated 
[26].
Strengths
To our knowledge, this study is the first to provide esti-
mates of ASP burden related to breast cancer in Zam-
bia, Uganda, and Namibia. Major strengths of this study 
were its multi-country design and large sample size; the 
use of a common protocol and data collection system for 
all four study sites, and of mHealth technology for study 
management, data collection and active follow-up of the 
participants. With the exception of Zambia, where an 
interruption of follow-up led to irreversible losses to fol-
low-up, mHealth has ensured very few losses to follow-
up in ABC-DO, and timely death notification [16]. The 
use of the validated EORTC-QLQ-Br23 questionnaire, 
a quality-of-life questionnaire with a special module for 
breast cancer patients, allowed us to capture accurate, 
affordable, and reproducible measures of ASP experi-
enced by women in our cohort. Our study demonstrated 
that this questionnaire can be used to monitor breast 
cancer survivors across different countries and ethnicities 
in SSA, similarly to what has been shown in HICs [17]. 
Our large study population and relatively high number of 
arm and shoulder outcomes enabled us to obtain reliable 
and accurate estimates of ASP burden, and to study their 
determinants in the Sub-Saharan setting.
Limitations
Our study population may not be representative of all 
breast cancer patients in SSA and the frequency of ASP. 
This is because recruitment was hospital-based, and 
some breast cancer cases may not seek care or may not 
be referred. However, hospital settings were tertiary 
centres, which is often the only treatment centre in the 
country and participation rate was very high (about 99%). 
After the baseline interview, at each 3-month follow-up 
contact, women were asked to report whether they had 
experienced ASP in the previous week. At the time of the 
first EORTC-QLQ-Br23 questionnaire, some women had 
already experienced an ASP. Therefore, our estimates are 
a proxy for incidence of ASP in this population because 
the baseline rates of ASP could not be determined in 
our population and those that occurred in between the 
3-month follow-up interviews may have been missed. 
Moreover, EORTC-QLQ-Br23 questions did not specify 
the side affected by ASP. In light of these considerations, 
we would advise future studies focussed on ASPs to (1) 
perform clinical measurements whenever possible; (2) 
ascertain a time-stamped history of ASPs at the time of 
diagnosis; (3) for each of the above, separately ascertain 
ASPs for the affected and contralateral breast and, in 
parallel, obtain laterality information for all treatments 
administered. As compared to objective measurement, 
patients’ self-reports of arm swelling have been shown to 
have high sensitivity, but only moderate specificity [30], 
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with the resulting false-positives leading to an over-esti-
mation of the frequency of ASP. We improved specific-
ity by only considering moderate to severe self-reported 
arm symptoms as indicative of ASP, as was done in other 
studies [5, 18, 19]. Moreover, the use of a validated ques-
tionnaire and standardized procedures to collect data on 
ASP limited the impact of misclassification on the study 
results. In our cohort, as the vast majority of women who 
received surgery got a mastectomy and data on axillary 
management was lacking, we were not able to analyse 
the impact of breast surgery type or axillary management 
technique on occurrence of ASP.
Research implications
This study highlights the high frequency of ASP following 
a breast cancer diagnosis in SSA as well as the presence of 
marked differences between countries and, in Namibia, 
also between ethnic groups. Indeed, the cost of breast 
cancer-related ASP is not only physical or emotional by 
lowering a woman’s quality-of-life, but it may also have 
financial consequences, notably by impacting on a wom-
an’s ability to work, or by engendering higher medical 
needs and costs (e.g. in the case of repeated infections 
due to lymphedema) [4, 31–33]. This may result in dra-
matic consequences on a woman’s ability to get appro-
priate care and take care of her family. Thus, identifying 
modifiable risk factors of ASP that could be targeted by 
future interventions is crucial to help preventing ASP in 
SSA. Further research is needed to better understand the 
impact of treatment on the occurrence of ASP in this set-
ting (e.g. studies with complete treatment data including 
quality of surgery and after care, chemotherapy adminis-
tration mode and associated side-effects, studies compar-
ing women’s pain score pre- and post-surgery).
As WHO launches its Global Breast Cancer Initiative 
in 2021, improving the diagnosis, prevention, and man-
agement of ASP in LMICs is important. Breast cancer 
care and survivorship programmes need to be developed 
in SSA, and should combine educational, financial, and 
emotional support components to significantly improve 
breast cancer patient’s quality-of-life and reduce the 
burden of ASP [25, 34–36]. These programmes should 
address ASP awareness, prevention, detection, and man-
agement. Moreover, they would need to reach breast 
cancer patients, health care professionals and also tradi-
tional healers, as these play an important role in cancer 
care delivery in this setting [37]. Affordable self-man-
agement measures should be emphasized and could be 
implemented in settings where access to care is lacking, 
and women should have access to physical and decon-
gestive therapies whenever possible. Moreover, down-
staging breast cancer is crucial to further reduce ASP 
burden in SSA, by raising awareness of this disease and 
by promoting its early detection in the region, especially 
among underprivileged populations who are the most at 
risk of late breast cancer diagnosis.
Conclusion
This study provides up-to-date estimates of ASP bur-
den in women living with breast cancer in SSA and gives 
insights on their determinants. In this setting, women 
affected by breast cancer are at high risk of reporting an 
ASP that may significantly impair their quality-of-life 
and contribute to worsen social inequities. To reduce the 
burden of ASP, appropriate breast cancer downstaging 
strategies, as well as patient and survivorship care pro-
grammes that include long-term surveillance, are needed.
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